Conall Watson MPharm PhD FFPH is Head of Vaccine Research and Senior Research Fellow in Vaccine Epidemiology at ERGO. He also spends half his time as a practising consultant in health protection for Public Health England.

Conall’s research interests are around emerging diseases which have the potential to be prevented through vaccination, and evidence-informed communicable disease control more broadly. During the 2014-2015 Ebola emergency, as part of a World Health Organization-led partnership, he jointly designed a novel “ring-vaccination” cluster randomised trial of the rVSV-ZEBOV Ebola vaccine. This demonstrated high efficacy in Guinea and led to wider deployment of the vaccine in West Africa and more recently in the Democratic Republic of the Congo.

Conall leads the Oxford component of a multi-institution NIHR project called VEEPED (Vaccine Efficacy Evaluation for Priority Emerging Diseases) which applies mathematical modelling and infectious disease epidemiology for the design of potential vaccine efficacy studies for emerging diseases. Conall is a member of the WHO R&D Blueprint for epidemic preparedness working group on vaccine trial designs.

Selected publications

Robert A, Edmunds WJ, Watson CH, Henao-Restrepo AM, Gsell P-S, Williamson E, et al. Determinants of transmission risk during the late stage of the West African Ebola epidemic. Am J Epi 2019, kwz090

Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017 Feb 3;389(10068):505–18.

Watson CH, Baker S, Lau CL, Rawalai K, Taufa M, Coriakula J, et al. A cross-sectional seroepidemiological survey of typhoid fever in Fiji. PLoS Negl Trop Dis. 2017 Jul 20;11(7):e0005786.

Ebola Ça Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 2015 Jul 27;351:H3740.